Neurocrine Biosciences, Inc. (NBIX) news stock charts
Neurocrine Biosciences, Inc. (NBIX) Investment Summary:
We were originally incorporated in California in January 1992 and were reincorporated in Delaware in May 1996. We discover, develop and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders. We currently have eight programs in various stages of research and development, including five programs in clinical development. While we independently develop many of our product candidates, we have entered into a collaboration for two of our programs. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f02%2f11%2f0000936392-08-000107.html#FIS_BUSINESS"www.neurocrine.com
65 Employees
Founded in 1992
NEUROCRINE BIOSCIENCES INC (NBIX:NASDAQ)
LAST $2.69 USD
CHANGE TODAY +0.11 4.26%
VOLUME 322.8K
As of 8:10 PM 03/18/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of NEUROCRINE BIOSCIENCES INC (NBIX)
|
OPEN
$2.60
|
PREVIOUS CLOSE
$2.58
|
|
|
DAY HIGH
$2.72
|
DAY LOW
$2.55
|
|
|
52 WEEK HIGH
03/23/09 - $4.25
|
52 WEEK LOW
11/30/09 - $1.94
|
|
|
MARKET CAP
143.0M
|
AVERAGE VOLUME 10 D
673.4K
|
|
|
EPS TTM
$-1.17
|
SHARES OUTSTANDING
53.2M
|
|
|
NBIX Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Neurocrine Biosciences closes stock offering
AP Digital - 03/17/2010 7:12 AM ET
Key developments for NEUROCRINE BIOSCIENCES INC (NBIX)
Neurocrine Biosciences Inc. Appoints William H. Rastetter to the Board of Directors; Amends Section 3.2 of its Bylaws
02/9/2010
Neurocrine Biosciences Inc. announced that effective as of February 4, 2010, the Board of Directors of the company, upon recommendation of its Nominating and Corporate Governance Committee, appointed William H. Rastetter, Ph.D. to the Board of Directors. Dr. Rastetter is a Class III director and his initial term expires at Neurocrines 2011 annual meeting of stockholders. Dr. Rastetter is a partner in Venrock. In December 2009, certain investment funds affiliated with Venrock acquired approximately 4.8 million shares of Neurocrines common stock in a privately negotiated transaction for aggregate gross proceeds of approximately $10.0 million. On February 3, 2010, the Board of Directors of the company amended Section 3.2 of its Bylaws to provide that the Board of Directors shall consist of nine members. Prior to the amendment, Section 3.2 of Neurocrines Bylaws provided that the Board of Directors shall consist of eight members.
Neurocrine Biosciences Inc. expected to Report Q1 2010 Results on May 5, 2010. This event was calculated by Capital IQ (Created on February 3, 2010).
02/3/2010
Neurocrine Biosciences Inc. expected to Report Q1 2010 Results on May 5, 2010. This event was calculated by Capital IQ (Created on February 3, 2010).
Neurocrine Biosciences Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2009
02/3/2010
Neurocrine Biosciences Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2009. For the quarter, the company reported a net loss of $7.9 million or $0.20 loss per share compared to a net loss of $28.9 million or $0.75 loss per share for the same period last year. Revenues for the fourth quarter of 2009 and 2008 were $0.7 million. Loss from operations was $8.980 million against $30.715 million of previous year period. For the year ended December 31, 2008, the company had a net loss of $51.0 million or $1.30 loss per share compared to a net loss of $88.6 million or $2.30 loss per share in 2008. The decrease in net loss is primarily the result of cost control measures throughout 2009. Revenues for the year ended December 31, 2009 were $3.0 million compared with $4.0 million for 2008. The decrease in revenues for the year ended December 31, 2009 is primarily due to a $1.0 million milestone recognized during 2008. Loss from operations was $53.670 million against $87.298 million of previous year.
Neurocrine Biosciences, Inc. financial resources
NBIX Competitors
| Company | Last | Change |
| Bristol-Myers Squibb Co | $26.07 USD | +0.09 |
| Eli Lilly & Co | $36.36 USD | +0.14 |
| Forest Laboratories Inc | $31.47 USD | -0.20 |
| King Pharmaceuticals Inc | $12.40 USD | -0.04 |
| Takeda Pharmaceutical Co Ltd | ¥4,290 JPY | +70.00 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | NBIX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 34.7x |
|
| Price/Book | 28.7x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 27.9x |
|
|
NBIX |
||
|
NBIX transactions
| Type Date |
Target |
|
Private Placement
December 16, 2009 |
-- |
More Recent Financial News About Neurocrine Biosciences, Inc.
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
2010-03-17 07:33:02
Quote: NEUROCRINE BIOSCIENCES INCRequest a Trial to NEW EDGAR Online Pro
Form
8-K for
NEUROCRINE BIOSCIENCES INC
16-Mar-2010Other Events, Financial Statements and Exhibits
Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any in...Read article
Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
2010-03-17 07:33:02
Quote: About Neurocrine BiosciencesNeurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine-related diseases and disorders.In addition to historical facts, this press release contains forward-looking statements that invo...Read article
Neurocrine Biosciences, Inc. Prices Common Stock Offering
2010-03-16 04:59:26
Quote: About Neurocrine BiosciencesNeurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine-related diseases and disorders.In addition to historical facts, this press release contains forward-looking statements that invo...Read article
Neurocrine Announces Proposed Public Offering of Common Stock
2010-03-16 04:59:26
Quote: About Neurocrine BiosciencesNeurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine-related diseases and disorders.In addition to historical facts, this press release contains forward-looking statements that invo...Read article
Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
2010-03-16 04:59:25
Quote: SAN DIEGO, March 10NasdaqNBIXNews) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Roth 22nd Annual OC Growth Conference in Laguna Niguel. The live presentation takes place Tuesday, March 16, 2010 at 12:30 p.m. Eastern Time (ET)/9:30 a.m. Pacific Timehttp://www.neurocrine.com. If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine ...Read article
Neurocrine Biosciences to Present at the 30th Annual Cowen & Co. Health Care Conference
2010-03-16 04:59:25
Quote: SAN DIEGO, March 8NasdaqNBIXNews) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 30th Annual Cowen & Co. Health Care Conference in Boston. The live presentation takes place Wednesday, March 10, 2010 at 9:30 a.m. Eastern Time (ET)/6:30 a.m. Pacific Timehttp://www.neurocrine.com. If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrin...Read article
Neurocrine falls after pricing stock offer
2010-03-16 04:59:25
Quote: NEW YORK (AP) -- Shares of Neurocrine Biosciences Inc. sank Friday after the biotechnology priced a public offering of new stock, saying it expects to raise $20 million from the sale.The San Diego company said it plans to sell 9.1 million shares at $2.20 per share. That's a 15.4-percent discount to its closing price of $2.60 on Thursday. The underwriters of the offering will have the option to buy another 1.4 million shares to cover over allotments.The offering closes Wednesday. Neurocrine had 4...Read article
Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
2010-03-11 07:10:06
Quote: SAN DIEGO, March 10NasdaqNBIXNews) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Roth 22nd Annual OC Growth Conference in Laguna Niguel. The live presentation takes place Tuesday, March 16, 2010 at 12:30 p.m. Eastern Time (ET)/9:30 a.m. Pacific Timehttp://www.neurocrine.com. If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine ...Read article
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
2010-03-11 07:10:06
Quote: Read article
Neurocrine Biosciences to Present at the 30th Annual Cowen & Co. Health Care Conference
2010-03-09 01:34:36
Quote: SAN DIEGO, March 8NasdaqNBIXNews) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 30th Annual Cowen & Co. Health Care Conference in Boston. The live presentation takes place Wednesday, March 10, 2010 at 9:30 a.m. Eastern Time (ET)/6:30 a.m. Pacific Timehttp://www.neurocrine.com. If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrin...Read article
Neurocrine Biosciences, Inc. Prices Common Stock Offering
2010-03-08 02:28:23
Quote: About Neurocrine BiosciencesNeurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine-related diseases and disorders.In addition to historical facts, this press release contains forward-looking statements that invo...Read article
HEADLINE STOCKS-U.S. small/midcap stocks on the move on March 5
2010-03-08 02:28:22
Keywords: Integrated telecommunication services,Telecommunication services (sector),Commercial services and supplies (industry group),Industrial machinery,Machinery,United States of America,Pharmaceuticals (sub-industry),Electrical components and equipment,Semicond
Quote: [ID:nWNAB5602] NEUROCRINE BIOSCIENCES (NBIX.O), $2.30, down 12 pct The biopharmaceutical company priced its common stock
offering. [ID:nWNAB5997] STANDARD MOTOR PRODUCTS (SMP.N), $10.34, up 20 pct Shares rose after the company posted better-than-expected
quarterly results. [ID:nWNAB5957] CRYOLIFE INC (CRY.N), $7.02, down 6 pct The company said it received a notice from a German patent
court on Tuesday that a patent on its main product, a surgical
adhesive called BioGlue, will be declared invalid...Read article
General Moly, YM BioSciences: Early Volume Plays
2010-03-08 02:28:22
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Robert Holmes ,Winners of the Day
Quote: NEW YORK (TheStreet) -- Several stocks trading near $5 were moving on above-average volume during Friday's session.Neurocrine Biosciences NBIX) dropped by 40 cents, or 15.4%, to $2.20 after the company priced an offering of 9.1 million shares of its common stock at $2.20 per share. Volume topped 1 million shares, compared to the 50-day average daily volume of 79,000, according to the Nasdaq.YM BioSciences YMI) fell by 26 cents, or 18.7%, to $1.13 after the company said it will raise $15 million ...Read article
Neurocrine falls after pricing stock offer
2010-03-08 02:28:21
Quote: NEW YORK (AP) -- Shares of Neurocrine Biosciences Inc. sank Friday after the biotechnology priced a public offering of new stock, saying it expects to raise $20 million from the sale.The San Diego company said it plans to sell 9.1 million shares at $2.20 per share. That's a 15.4-percent discount to its closing price of $2.60 on Thursday. The underwriters of the offering will have the option to buy another 1.4 million shares to cover over allotments.The offering closes Wednesday. Neurocrine had 4...Read article
Neurocrine Announces Proposed Public Offering of Common Stock
2010-03-05 03:19:26
Quote: About Neurocrine BiosciencesNeurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine-related diseases and disorders.In addition to historical facts, this press release contains forward-looking statements that invo...Read article
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2009 Results
2010-02-15 05:28:17
Quote: 3 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and year ended December 31, 2009. For the three months ended December 31, 2009, the Company reported a net loss of $7.9 million or $0.20 loss per share compared to a net loss of $28.9 million or $0.75 loss per share for the same period last year. For the year ended December 31, 2009, the Company had a net loss of $51.0 million or $1.30 loss per share compared to a ...Read article
Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
2010-02-15 05:28:16
Quote: 8 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has appointed William H. Rastetter Ph.D. to its Board of Directors effective immediately. He is the current Chairman and Chief Executive Officer of Receptos, Inc., and former Executive Chairman of Biogen Idec, Inc."We are very pleased to welcome Bill Rastetter to our Board of Directors," said Joseph A. Mollica, Ph.D., Chairman of the Board of Neurocrine Biosciences. Â "The company is very fortunate ...Read article
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of I
2010-02-10 03:04:38
Quote: Read article
Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
2010-02-09 01:41:46
Quote: 8 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has appointed William H. Rastetter Ph.D. to its Board of Directors effective immediately. He is the current Chairman and Chief Executive Officer of Receptos, Inc., and former Executive Chairman of Biogen Idec, Inc."We are very pleased to welcome Bill Rastetter to our Board of Directors," said Joseph A. Mollica, Ph.D., Chairman of the Board of Neurocrine Biosciences. Â "The company is very fortunate ...Read article
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2009 Results
2010-02-05 07:57:24
Quote: 3 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and year ended December 31, 2009. For the three months ended December 31, 2009, the Company reported a net loss of $7.9 million or $0.20 loss per share compared to a net loss of $28.9 million or $0.75 loss per share for the same period last year. For the year ended December 31, 2009, the Company had a net loss of $51.0 million or $1.30 loss per share compared to a ...Read article
Would you like to leave a comment about Neurocrine Biosciences, Inc. NBIX
Find out what social network information about Neurocrine Biosciences, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Neurocrine Biosciences, Inc.'s Stock there is more great penny stock and market information at Realpennies